Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Deerfield Management Discloses Stake In Post-IPO Audentes Therapeutics (BOLD)

Page 1 of 14

James E. Flynn and his fund, Deerfield Management, have disclosed a stake in Audentes Therapeutics Inc (NASDAQ:BOLD), a company that has recently closed its initial public offering. According to a filing with the Securities and Exchange Commission, Flynn and Deerfield hold roughly 1.4 million shares, which account for some 6.68% of the company’s outstanding stock.

Audentes Therapeutics Inc (NASDAQ:BOLD) is a biotechnology company that aims to develop gene therapy for various rare diseases. The company sold 5 million shares at $15 apiece in its initial offering, raising $75 million that it plans to invest in its research work. Among the main conditions it is now studying are X-Linked myotubular myopathy, Crigler-Najjar Syndrome, and Pompe disease. The drug candidates for these three conditions are expected to produce preliminary results from their first trials during the second half of 2017.

Samuel Isaly‘s OrbiMed Advisors had also invested in Audentes Therapeutics Inc (NASDAQ:BOLD) before the initial public offering and was the largest shareholder with a 29.8% stake prior to the offering. Overall, since its inception in 2012, Audentes Therapeutics has raised $135.8 million in equity financing from various venture capitalists and private investors, as well as hedge funds.

Abbvie ABBV biopharmaceuticals cell blood dna gene stem test biotech research

RAJ CREATIONZS / shutterstock.com

You can access the original SEC filing by clicking here.

Ownership Summary Table

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
Deerfield Mgmt 0 514,424 0 514,424 514,424 2.45%
Deerfield Management Company 0 1,403,654 0 1,403,654 1,403,654 6.68%
Deerfield Mgmt III 0 889,230 0 889,230 889,230 4.23%
Deerfield Special Situations Fund 0 514,424 0 514,424 514,424 2.45%
Deerfield Private Design Fund III 0 889,230 0 889,230 889,230 4.23%
James E. Flynn 0 1,403,654 0 1,403,654 1,403,654 6.68%
James E. Flynn
James E. Flynn
Deerfield Management

Page 1 of 14 – SEC Filing

SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
SCHEDULE 13G
(Rule 13d-102)
INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED
PURSUANT TO RULE 13d-2(b)
(Amendment No. ) *

Audentes Therapeutics, Inc.


(Name of Issuer)

Common Stock, par value $0.00001 per share


(Title of Class of Securities)

05070R104


(CUSIP Number)

July 25, 2016


(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
 
¨ Rule 13d-1(b)
x Rule 13d-1(c)
¨ Rule 13d-1(d)
(Page 1 of 11 Pages)
__________________
* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
     The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
Follow Audentes Therapeutics Inc.
Trade (BOLD) Now!
Page 1 of 14
Loading Comments...